KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?

Alexander F Wang, Brian Hsueh, Bryan D Choi, Elizabeth R Gerstner, Gavin P Dunn

Curr Treat Options Oncol 25(5) 628-643

PMID38649630
PMCID-
DOI10.1007/s11864-024-01200-9
发表日期2024-04-22
摘要

摘要

Immunotherapy for glioblastoma (GBM) remains an intensive area of investigation. Given the seismic impact of cancer immunotherapy across a range of malignancies, there is optimism that harnessing the power of immunity will influence GBM as well. However, despite several phase 3 studies, there are still no FDA-approved immunotherapies for GBM. Importantly, the field has learned a great deal from the randomized studies to date. Today, we are continuing to better understand the disease-specific features of the microenvironment in GBM-as well as the exploitable antigenic characteristic of the tumor cells themselves-that are informing the next generation of immune-based therapeutic strategies. The coming phase of next-generation immunotherapies is thus poised to bring us closer to treatments that will improve the lives of patients with GBM.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。